Please ensure Javascript is enabled for purposes of website accessibility

Biotech Bankruptcies Hit Recent High in 2019

By Mark Prvulovic - Updated Jan 31, 2020 at 5:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Bankruptcies reached a high not seen since 2011, with opioid lawsuits playing a big role.

Biotech investors might have had an exciting year in 2019 with an impressive amount of new drug approvals. There were 14 notable bankruptcies last year as well, the highest since 2011. Although it's less common to see a company declare bankruptcy in the biotech sector than in other industries, there were a number of reasons why 2019 saw such a high bankruptcy rate.

Legal issues surrounding opioid lawsuits have been a major contributor to this high bankruptcy figure. Purdue Pharmawent out of business earlier in 2019 due to its involvement in manufacturing opioids. The company faces up to $12 billion in fines to settle its lawsuits.

Bankruptcy documents with a pen and some glasses resting on a table.

Image source: Getty Images.

Other smaller opioid manufacturers, such as Insys Therapeutics, have also filed for bankruptcy protection. In this case, the company's founder recently received a 5 year prison sentence for his role in bribing medical professionals and misleading insurance providers.

Potential 2020 opioid bankruptcies

With many opioid lawsuits still ongoing, there's a strong possibility that 2020 could have just as many bankruptcies -- or even more -- than 2019 did. Major healthcare giants such as Johnson & Johnson (JNJ 1.46%) have been hit with legal fines for their role in the opioid epidemic.

Some of the largest opioid manufacturers, such as Mckesson (MCK 2.19%) and Mallinckrodt (MNK), could face fines in the billions of dollars. Mallinckrodt, in particular, has lost the vast majority of its market value over the past 12-months, and could quite easily go bankrupt if it's hit by a large legal fine. Some analysts have argued that the stock could quickly fall down to the penny stock range in the future as litigation risks loom.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$182.29 (1.46%) $2.63
McKesson Corporation Stock Quote
McKesson Corporation
$321.55 (2.19%) $6.89
Mallinckrodt Public Limited Company Stock Quote
Mallinckrodt Public Limited Company
INSYS Therapeutics Stock Quote
INSYS Therapeutics

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.